Prognostic value of the MicroRNA-29 family in multiple human cancers: a meta-analysis and systematic review

Qi, Yan, Huang, Yalan, Pang, Lijuan, Gu, Wenyi, Wang, Ning, Hu, Jianming, Cui, Xiaobin, Zhang, Jun, Zhao, Jin, Liu, Chunxia, Zhang, Wenjie, Zou, Hong and Li, Feng (2017) Prognostic value of the MicroRNA-29 family in multiple human cancers: a meta-analysis and systematic review. Clinical and Experimental Pharmacology and Physiology, 44 4: 441-454. doi:10.1111/1440-1681.12726


Author Qi, Yan
Huang, Yalan
Pang, Lijuan
Gu, Wenyi
Wang, Ning
Hu, Jianming
Cui, Xiaobin
Zhang, Jun
Zhao, Jin
Liu, Chunxia
Zhang, Wenjie
Zou, Hong
Li, Feng
Title Prognostic value of the MicroRNA-29 family in multiple human cancers: a meta-analysis and systematic review
Journal name Clinical and Experimental Pharmacology and Physiology   Check publisher's open access policy
ISSN 1440-1681
0305-1870
Publication date 2017-04-01
Sub-type Article (original research)
DOI 10.1111/1440-1681.12726
Open Access Status Not yet assessed
Volume 44
Issue 4
Start page 441
End page 454
Total pages 14
Place of publication Richmond, VIC, Australia
Publisher Wiley-Blackwell Publishing Asia
Collection year 2018
Language eng
Abstract MicroRNAs (miRNAs) in cancer development have attracted much attention in recent years. miR-29 is known to critically affect cancer progression by functioning as a tumor suppressor. However, it may also act as an oncogene under certain situations. The prognostic value of the miR-29 family in cancer progression is still under debate and reported results are inconsistent. Therefore, we reported here a meta-analysis and systematic review to analyze the prognostic role of the miR-29 family in cancer. We screened 20 published studies and calculated pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS) or disease-free survival/recurrence-free survival (DFS/RFS). Our results showed that a low or absent expression of miR-29 family was significantly associated with poor OS (HR, 1.57; 95%CI, 1.18-2.08), and inferior to 5-year DFS/RFS (HR, 1.89; 95%CI, 1.47-2.44). Analysis of individual miR-29 subtypes indicated that the low expression of miR-29a/b/c subtypes correlated with poor 5-year OS (miR-29a: HR, 1.99; 95%CI, 1.41-2.80; miR-29b: HR, 1.60; 95%CI, 1.18-2.17; miR-29c: HR, 1.69; 95%CI, 1.00-2.86), as well as poor 5-year DFS/RFS (miR-29b: HR, 1.70; 95%CI, 1.27-2.27). Ethnicity analysis demonstrated Asian patients with low expression of miR-29 were significantly correlated with poor OS (HR, 1.61; 95%CI, 1.16-2.23) and 5-year DFS/RFS (HR, 2.03; 95%CI, 1.50-2.74). Taken together, our analysis indicates that the low expression of miR-29 is associated with aggressiveness and poor prognosis of malignant neoplasms. More importantly, miR-29 might serve as a key biomarker for predicting the recurrence and progression of human cancers.
Keyword Malignant neoplasm
Meta-analysis
MicroRNA-29
Prognostic
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Australian Institute for Bioengineering and Nanotechnology Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 11 Apr 2017, 00:25:16 EST by Web Cron on behalf of Learning and Research Services (UQ Library)